Clinical Trials Browser

Phase 2 × OTHER × Platinum-Resistant Lung Small Cell Carcinoma × Clear all

NCT04607954 2026-01-06

Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer

Phase 2 Active not recruiting

Platinum-Resistant Lung Small Cell Carcinoma